Results 81 to 90 of about 16,768 (136)

Retraction Note: Toll-like receptor 9 agonist IMO cooperates with everolimus in renal cell carcinoma by interfering with tumour growth and angiogenesis. [PDF]

Br J Cancer
Damiano V, Rosa R, Formisano L, Nappi L, Gelardi T, Marciano R, Cozzolino I, Troncone G, Agrawal S, Veneziani BM, De Placido S, Bianco R, Tortora G.   +12 more
europepmc   +1 more source

Regionalization and regulation: impact on access to cancer treatment. [PDF]

Rev Saude Publica
Duarte LS, Shirassu MM, Ribeiro AG, Murta-Nascimento C, Fagundes MA, Luizaga CTM, Wünsch Filho V.   +6 more
europepmc   +1 more source

Contrasting outcomes of inherited <i>NOD2</i> loss-of-function variants on immunotherapy response in cancer. [PDF]

Proc Natl Acad Sci U S A
Bousdar N, Pérez-Ruiz E, Barragán I, Benítez JC, Rueda-Domínguez A, Oliver J.   +5 more
europepmc   +1 more source

177Lutetium-PSMA-I&T therapy for metastatic castration-resistant prostate cancer (mCRPC): the first multicenter real-world study of 177Lu-PSMA-I&T in Brazil. [PDF]

EJNMMI Rep
Bruzzi HF, Lopes GCK, Bekierman HBV, de Almeida SA, Pedrosa JA, Mosci C, Abboud HS, Magalhães C, Palazzio I, Fernandes L, da Silva VF, da Silva Andrade JT, Herchenhorn D.   +12 more
europepmc   +1 more source